Advances in AMD imaging.

摘要

Introduction New imaging modalities in the detection and management of age-related macular degeneration (AMD) have evolved significantly over the past few decades. The impetus for their development stems from the growing body of research that suggests that the current methods of neovascular AMD detection such as fluorescein angiography (FA) and Amsler grid testing find, AMD too late in its course. The treatment in AMD with photodynamic therapy trial (TAP) and verteporfin in photodynamic therapy trials confirmed that the lesion size was the single most important factor in determining posttreatment outcome with an average lesion size at presentation of 3300 urn.1-3 These studies identified a linear correlation between lesion size and posttreatment visual loss. For example, a 1 disc area lesion correlated with a 1 line posttreatment loss and a 3.3 disc area lesion correlated with a 3 line posttreatment loss. Because at the time of diagnosis 40% of patients are legally blind and 80% of patients have subfoveal lesions, early diagnosis is vital.